Orris

These are slides, we'll be including to the ppt:- 1. Title Slide & Introduction 2.Objectives 3.Guideline Development Working Groups. 4. Methods 5. Clinical Practice Guidelines:- 5.1 Defination & Diagnosis Of Asthma 5.2 Recognizing & Managing acute exacerbations 5.3 Principles of Long term Management in Asthma 5.4 Education and Prevention of Asthma 5.5 Risk Evaluation 6.Summary 7. Refrences 8.Ending Slide.. these are the topic in slides of ppt .. my topic is just 5.3 so give me answers accordingly to the given ppt for 5.3 sections .. provide me content for 5 slides just from the given pdf .. if pictures possible provide me that also nd make me ppt for this alone pls

Reading File
Reading File
Reading File
Running Command

python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/works…

Running Command

python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/works…

Running Command

python3 -c " import fitz # PyMuPDF import os pdf_path = '/home/daytona/workspa…

Running Command

python3 -c " from pypdf import PdfReader import os pdf_path = '/home/daytona/wo…

Running Command

ls /home/daytona/workspace/asthma_5_3/images/

Writing File

~/asthma_5_3/create_ppt.js

const pptxgen = require("pptxgenjs");
const fs = require("fs");
const path = require("path");

const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "5.3 Principles of Long-term Management in Asthma";

// ─── COLOR PALETTE ───────────────────────────────────────────────
const DARK_BLUE   = "0D2B5E";  // dominant background / header fill
const MED_BLUE    = "1A4A8A";  // section headers
const ACCENT      = "2EAADC";  // accent lines, icons, highlights
const LIGHT_BG    = "EDF4FB";  // slide background (light)
const WHITE       = "FFFFFF";
const DARK_TEXT   = "1A1A2E";
const SUBTEXT     = "4A5568";
const ORANGE      = "E8813A";  // key-point highlights

// helper – load image as base64
function imgBase64(filePath) {
  const ext = path.extname(filePath).slice(1).toLowerCase();
  const mime = ext === "jpg" ? "image/jpeg" : `image/${ext}`;
  const data = fs.readFileSync(filePath);
  return `${mime};base64,${data.toString("base64")}`;
}

const IMG_DIR = "/home/daytona/workspace/asthma_5_3/images/";

// ══════════════════════════════════════════════════════════════════
//  SLIDE 1 – Section Title + Overview + Assess-Adjust-Review Cycle
// ══════════════════════════════════════════════════════════════════
{
  const slide = pres.addSlide();

  // Background
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: LIGHT_BG }, line: { color: LIGHT_BG } });

  // Left dark panel
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 3.5, h: "100%", fill: { color: DARK_BLUE }, line: { color: DARK_BLUE } });

  // Accent bar on left panel
  slide.addShape(pres.ShapeType.rect, { x: 3.3, y: 0, w: 0.2, h: "100%", fill: { color: ACCENT }, line: { color: ACCENT } });

  // Slide number on left
  slide.addText("5.3", { x: 0.2, y: 0.2, w: 3.0, h: 0.7, fontSize: 40, bold: true, color: ACCENT, fontFace: "Calibri" });

  // Title text
  slide.addText("Principles of Long-term\nManagement in Asthma", {
    x: 0.25, y: 0.95, w: 3.0, h: 1.8,
    fontSize: 16, bold: true, color: WHITE, fontFace: "Calibri",
    align: "left", valign: "top"
  });

  // Subtitle on left
  slide.addText("Clinical Practice Guidelines\nPhilippines (GINA 2021 Adopted)", {
    x: 0.25, y: 2.85, w: 3.0, h: 1.0,
    fontSize: 10, color: "A8C8E8", fontFace: "Calibri", italic: true
  });

  // Right side – main content
  slide.addText("Overview of Long-term Asthma Management", {
    x: 3.7, y: 0.25, w: 6.1, h: 0.55,
    fontSize: 18, bold: true, color: DARK_BLUE, fontFace: "Calibri"
  });

  // Underline
  slide.addShape(pres.ShapeType.rect, { x: 3.7, y: 0.78, w: 6.1, h: 0.04, fill: { color: ACCENT }, line: { color: ACCENT } });

  // Three components boxes
  const comps = [
    { icon: "💊", title: "Pharmacologic Management", desc: "Controller, reliever & add-on therapies across treatment steps (KQ 4)" },
    { icon: "🛡️", title: "Non-Pharmacologic Strategies", desc: "Prevention, symptom control & trigger avoidance (KQ 6, 7)" },
    { icon: "📋", title: "Self / Parental Management", desc: "Asthma education, skill training & written action plans (KQ 3, 8)" },
  ];

  comps.forEach((c, i) => {
    const bx = 3.75 + i * 2.05;
    // Card
    slide.addShape(pres.ShapeType.rect, { x: bx, y: 0.92, w: 1.95, h: 1.55,
      fill: { color: WHITE }, line: { color: ACCENT, pt: 1.5 }, rectRadius: 0.08 });
    slide.addText(c.icon, { x: bx, y: 0.98, w: 1.95, h: 0.45, fontSize: 22, align: "center" });
    slide.addText(c.title, { x: bx + 0.08, y: 1.4, w: 1.8, h: 0.45,
      fontSize: 9, bold: true, color: DARK_BLUE, fontFace: "Calibri", align: "center" });
    slide.addText(c.desc, { x: bx + 0.08, y: 1.82, w: 1.8, h: 0.6,
      fontSize: 7.5, color: SUBTEXT, fontFace: "Calibri", align: "center" });
  });

  // Long-term goals heading
  slide.addText("Long-term Goals (GINA 2021)", {
    x: 3.7, y: 2.58, w: 6.1, h: 0.38,
    fontSize: 13, bold: true, color: MED_BLUE, fontFace: "Calibri"
  });

  const goals = [
    "Achieve good symptom control and maintain normal activity levels",
    "Minimize risk of asthma-related deaths, exacerbations, persistent airflow limitation and side effects",
    "Provide patients and caregivers with suitable information and training to manage asthma in partnership with healthcare providers",
  ];
  goals.forEach((g, i) => {
    slide.addShape(pres.ShapeType.rect, { x: 3.7, y: 3.02 + i * 0.65, w: 0.04, h: 0.42, fill: { color: ORANGE }, line: { color: ORANGE } });
    slide.addText(g, { x: 3.82, y: 3.02 + i * 0.65, w: 5.95, h: 0.45,
      fontSize: 9.5, color: DARK_TEXT, fontFace: "Calibri", valign: "middle" });
  });

  // Assess-Adjust-Review label + image (page 1 image = Figure 2)
  slide.addText("Core Cycle: Assess → Adjust → Review", {
    x: 3.7, y: 5.05, w: 4.5, h: 0.38,
    fontSize: 11, bold: true, color: MED_BLUE, fontFace: "Calibri"
  });
  // Use the page1 image (Figure 2)
  try {
    slide.addImage({ data: imgBase64(IMG_DIR + "p1_X214.jpg"), x: 6.0, y: 4.65, w: 3.8, h: 0.85 });
  } catch(e) {}

  // Source footer
  slide.addText("Source: Philippine Clinical Practice Guidelines on Asthma (GINA 2021 Adopted)", {
    x: 3.7, y: 5.42, w: 6.1, h: 0.2, fontSize: 7, italic: true, color: "999999", fontFace: "Calibri"
  });
}

// ══════════════════════════════════════════════════════════════════
//  SLIDE 2 – Pharmacological Management: Treatment Steps by Age
// ══════════════════════════════════════════════════════════════════
{
  const slide = pres.addSlide();
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: LIGHT_BG }, line: { color: LIGHT_BG } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.7, fill: { color: DARK_BLUE }, line: { color: DARK_BLUE } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0.7, w: "100%", h: 0.06, fill: { color: ACCENT }, line: { color: ACCENT } });

  slide.addText("5.3  Pharmacological Management — Treatment Steps by Age Group", {
    x: 0.25, y: 0.1, w: 9.5, h: 0.52,
    fontSize: 16, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Three age columns
  const cols = [
    {
      title: "Children < 6 yrs",
      color: "1A6B3C",
      steps: [
        "Step 1: Inhaled SABA for relief (infrequent viral wheeze)",
        "Step 2: Daily low-dose ICS (≥3 episodes/yr or symptoms not controlled) – give for at least 3 months",
        "Step 3: Double low-dose ICS OR low-dose ICS + LTRA",
        "Step 4: Refer to asthma specialist",
        "Preferred device: pMDI + spacer with face mask (≤3 yrs); pMDI + spacer with mouthpiece (4–5 yrs)",
      ]
    },
    {
      title: "Children 6–11 yrs",
      color: "1A4A8A",
      steps: [
        "Step 1: Low-dose ICS whenever SABA is taken (symptoms <2×/month)",
        "Step 2: Daily low-dose ICS + as-needed SABA",
        "Step 3: Medium-dose ICS OR low-dose ICS-LABA OR MART (ICS-formoterol as maintenance & reliever)",
        "Step 4: Medium-dose ICS-LABA + as-needed SABA or MART",
        "Step 5: Refer for expert assessment, add-on therapy & phenotyping",
      ]
    },
    {
      title: "Adolescents 12–18 yrs",
      color: "7B2D8B",
      steps: [
        "Track 1 (preferred): As-needed low-dose ICS-formoterol across all steps",
        "Track 2 (alternate): SABA when ICS-formoterol not available/preferred",
        "Steps 1–2: As-needed ICS-formoterol OR daily low-dose ICS maintenance",
        "Step 3: MART (low-dose ICS-formoterol maintenance + reliever)",
        "Steps 4–5: Medium-dose ICS-formoterol MART or ICS-LABA; consider LAMA add-on",
      ]
    }
  ];

  cols.forEach((col, i) => {
    const bx = 0.2 + i * 3.3;
    // Header
    slide.addShape(pres.ShapeType.rect, { x: bx, y: 0.85, w: 3.1, h: 0.45, fill: { color: col.color }, line: { color: col.color }, rectRadius: 0.05 });
    slide.addText(col.title, { x: bx, y: 0.85, w: 3.1, h: 0.45, fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri", align: "center", valign: "middle" });

    col.steps.forEach((step, si) => {
      // Step number box
      slide.addShape(pres.ShapeType.rect, { x: bx, y: 1.38 + si * 0.78, w: 0.22, h: 0.62, fill: { color: col.color }, line: { color: col.color } });
      slide.addText(`${si + 1}`, { x: bx, y: 1.38 + si * 0.78, w: 0.22, h: 0.62, fontSize: 9, bold: true, color: WHITE, fontFace: "Calibri", align: "center", valign: "middle" });
      // Step text
      slide.addShape(pres.ShapeType.rect, { x: bx + 0.22, y: 1.38 + si * 0.78, w: 2.88, h: 0.62, fill: { color: WHITE }, line: { color: col.color, pt: 0.75 } });
      slide.addText(step, { x: bx + 0.28, y: 1.4 + si * 0.78, w: 2.76, h: 0.58, fontSize: 7.8, color: DARK_TEXT, fontFace: "Calibri", valign: "middle" });
    });
  });

  // Key note
  slide.addShape(pres.ShapeType.rect, { x: 0.2, y: 5.28, w: 9.6, h: 0.3, fill: { color: "FFF3CD" }, line: { color: ORANGE, pt: 1 } });
  slide.addText("⚠  SABA-only treatment is no longer recommended. Low-dose ICS or ICS-formoterol should be initiated once asthma is confirmed (Recommendation 4a).", {
    x: 0.3, y: 5.3, w: 9.4, h: 0.26, fontSize: 8.5, color: "6B4226", fontFace: "Calibri", bold: true
  });

  slide.addText("Source: Philippine CPG on Asthma (GINA 2021 Adopted)", {
    x: 0.2, y: 5.56, w: 9.6, h: 0.16, fontSize: 7, italic: true, color: "999999", fontFace: "Calibri"
  });
}

// ══════════════════════════════════════════════════════════════════
//  SLIDE 3 – Treatment Step Figures (visual diagrams from PDF)
// ══════════════════════════════════════════════════════════════════
{
  const slide = pres.addSlide();
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: LIGHT_BG }, line: { color: LIGHT_BG } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.7, fill: { color: MED_BLUE }, line: { color: MED_BLUE } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0.7, w: "100%", h: 0.05, fill: { color: ACCENT }, line: { color: ACCENT } });

  slide.addText("5.3  Clinical Pathway Figures — Pharmacological Treatment Steps", {
    x: 0.25, y: 0.1, w: 9.5, h: 0.52, fontSize: 16, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Fig 3 – children <6 yrs (p5 image)
  slide.addText("Figure 3: Treatment Steps for Children < 6 yrs", {
    x: 0.3, y: 0.82, w: 4.5, h: 0.32, fontSize: 10, bold: true, color: DARK_BLUE, fontFace: "Calibri"
  });
  try {
    slide.addImage({ data: imgBase64(IMG_DIR + "p5_X225.jpg"), x: 0.3, y: 1.15, w: 4.5, h: 3.5 });
  } catch(e) {
    slide.addText("[Figure 3: Treatment Steps < 6 yrs]", { x: 0.3, y: 1.15, w: 4.5, h: 3.5, fontSize: 12, color: SUBTEXT, align: "center", valign: "middle" });
  }

  // Fig 4 – children 6-11 yrs (p8 image)
  slide.addText("Figure 4: Clinical Pathway for Children 6–11 yrs", {
    x: 5.1, y: 0.82, w: 4.7, h: 0.32, fontSize: 10, bold: true, color: DARK_BLUE, fontFace: "Calibri"
  });
  try {
    slide.addImage({ data: imgBase64(IMG_DIR + "p8_X232.jpg"), x: 5.1, y: 1.15, w: 4.7, h: 3.5 });
  } catch(e) {
    slide.addText("[Figure 4: Clinical Pathway 6–11 yrs]", { x: 5.1, y: 1.15, w: 4.7, h: 3.5, fontSize: 12, color: SUBTEXT, align: "center", valign: "middle" });
  }

  // Bottom labels
  slide.addText("Adapted from GINA 2021 | Philippine CPG on Asthma", {
    x: 0.3, y: 4.75, w: 9.4, h: 0.25, fontSize: 8, italic: true, color: "999999", fontFace: "Calibri", align: "center"
  });

  // Fig 5 note
  slide.addShape(pres.ShapeType.rect, { x: 0.3, y: 5.06, w: 9.4, h: 0.45, fill: { color: WHITE }, line: { color: MED_BLUE, pt: 1 }, rectRadius: 0.05 });
  slide.addText("Figure 5 (Adolescents 12–18 yrs): Track 1 uses as-needed ICS-formoterol as reliever across all Steps 1–5. Track 2 uses SABA as alternate reliever. MART (maintenance and reliever therapy) is preferred at Step 3 and above.", {
    x: 0.4, y: 5.1, w: 9.2, h: 0.38, fontSize: 8.5, color: DARK_TEXT, fontFace: "Calibri", valign: "middle"
  });
}

// ══════════════════════════════════════════════════════════════════
//  SLIDE 4 – Reviewing Response, Stepping Down & Referral
// ══════════════════════════════════════════════════════════════════
{
  const slide = pres.addSlide();
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: LIGHT_BG }, line: { color: LIGHT_BG } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.7, fill: { color: DARK_BLUE }, line: { color: DARK_BLUE } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0.7, w: "100%", h: 0.05, fill: { color: ACCENT }, line: { color: ACCENT } });

  slide.addText("5.3  Reviewing Response, Step-Down Strategy & Referral to Specialist", {
    x: 0.25, y: 0.1, w: 9.5, h: 0.52, fontSize: 15, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // LEFT COLUMN – Reviewing Response
  slide.addShape(pres.ShapeType.rect, { x: 0.2, y: 0.85, w: 4.6, h: 0.42, fill: { color: MED_BLUE }, line: { color: MED_BLUE }, rectRadius: 0.05 });
  slide.addText("Reviewing Response & Adjusting Treatment (GPS 4.1)", {
    x: 0.25, y: 0.85, w: 4.5, h: 0.42, fontSize: 10, bold: true, color: WHITE, fontFace: "Calibri", valign: "middle"
  });

  const reviewPoints = [
    "Review within 1–3 months and every 3–12 months thereafter",
    "After exacerbation/flare-up → follow up within 1 week",
    "Continue treatment ≥3 months to establish effectiveness",
    "Children <5 yrs: regularly assess if controller still needed (symptoms may remit)",
    "Assess: symptom control, exacerbation frequency, medication side effects, inhaler technique & adherence",
  ];
  reviewPoints.forEach((pt, i) => {
    slide.addShape(pres.ShapeType.ellipse, { x: 0.25, y: 1.35 + i * 0.55, w: 0.18, h: 0.18, fill: { color: ACCENT }, line: { color: ACCENT } });
    slide.addText(pt, { x: 0.5, y: 1.3 + i * 0.55, w: 4.2, h: 0.5, fontSize: 8.5, color: DARK_TEXT, fontFace: "Calibri", valign: "middle" });
  });

  // Step-down figure
  try {
    slide.addText("Figure 6: Step-down Strategy", { x: 0.25, y: 4.12, w: 4.5, h: 0.28, fontSize: 9, bold: true, color: MED_BLUE, fontFace: "Calibri" });
    slide.addImage({ data: imgBase64(IMG_DIR + "p12_X243.jpg"), x: 0.25, y: 4.38, w: 4.5, h: 1.2 });
  } catch(e) {}

  // RIGHT COLUMN – Step Down + Referral
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 0.85, w: 4.7, h: 0.42, fill: { color: "1A6B3C" }, line: { color: "1A6B3C" }, rectRadius: 0.05 });
  slide.addText("Step-Down Principles (Section 11.4)", {
    x: 5.15, y: 0.85, w: 4.6, h: 0.42, fontSize: 10, bold: true, color: WHITE, fontFace: "Calibri", valign: "middle"
  });

  const stepDownPts = [
    "Reduce ICS dose by 25–50% every 3 months once good control achieved for ≥3 months",
    "Provide written asthma action plan with instructions to revert to previous treatment if needed",
    "Choose appropriate timing: no respiratory infection, not travelling, not pregnant",
    "Do NOT completely withdraw ICS unless temporarily needed to confirm diagnosis",
    "Monitor via symptom control and/or peak expiratory flow (PEF) + follow-up visit",
  ];
  stepDownPts.forEach((pt, i) => {
    slide.addShape(pres.ShapeType.ellipse, { x: 5.15, y: 1.35 + i * 0.55, w: 0.18, h: 0.18, fill: { color: ORANGE }, line: { color: ORANGE } });
    slide.addText(pt, { x: 5.4, y: 1.3 + i * 0.55, w: 4.3, h: 0.5, fontSize: 8.5, color: DARK_TEXT, fontFace: "Calibri", valign: "middle" });
  });

  // Referral indications box
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 4.15, w: 4.7, h: 1.42, fill: { color: "FFF3CD" }, line: { color: ORANGE, pt: 1.5 }, rectRadius: 0.06 });
  slide.addText("⚠  Indications for Specialist Referral (Rec. 4f)", { x: 5.2, y: 4.18, w: 4.5, h: 0.3, fontSize: 9.5, bold: true, color: "6B4226", fontFace: "Calibri" });
  const referrals = [
    "Difficulty confirming asthma diagnosis",
    "Persistent/uncontrolled asthma despite Step 4 treatment",
    "Risk factors for asthma-related death (near-fatal attack, anaphylaxis)",
    "Significant treatment side effects / need for long-term oral corticosteroids",
    "Suspected occupational asthma or complicated sub-types",
  ];
  referrals.forEach((r, i) => {
    slide.addText(`• ${r}`, { x: 5.2, y: 4.5 + i * 0.2, w: 4.5, h: 0.2, fontSize: 8, color: DARK_TEXT, fontFace: "Calibri" });
  });

  slide.addText("Source: Philippine CPG on Asthma (GINA 2021 Adopted)", {
    x: 0.2, y: 5.56, w: 9.6, h: 0.16, fontSize: 7, italic: true, color: "999999", fontFace: "Calibri"
  });
}

// ══════════════════════════════════════════════════════════════════
//  SLIDE 5 – Difficult-to-Treat Asthma, FeNO Guidance & Self-Management
// ══════════════════════════════════════════════════════════════════
{
  const slide = pres.addSlide();
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: LIGHT_BG }, line: { color: LIGHT_BG } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.7, fill: { color: DARK_BLUE }, line: { color: DARK_BLUE } });
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0.7, w: "100%", h: 0.05, fill: { color: ACCENT }, line: { color: ACCENT } });

  slide.addText("5.3  Difficult-to-Treat Asthma, FeNO-Guided Therapy & Self-Management", {
    x: 0.25, y: 0.1, w: 9.5, h: 0.52, fontSize: 14.5, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // LEFT – Difficult-to-treat asthma
  slide.addShape(pres.ShapeType.rect, { x: 0.2, y: 0.85, w: 4.6, h: 0.42, fill: { color: "8B2020" }, line: { color: "8B2020" }, rectRadius: 0.05 });
  slide.addText("Difficult-to-Treat & Severe Asthma (Section 13)", {
    x: 0.25, y: 0.85, w: 4.5, h: 0.42, fontSize: 10, bold: true, color: WHITE, fontFace: "Calibri", valign: "middle"
  });

  const dtPts = [
    { label: "Difficult-to-treat:", text: "Uncontrolled despite medium/high-dose ICS + LABA, or requires high-dose treatment to maintain control" },
    { label: "Severe asthma:", text: "Remains uncontrolled despite maximally optimized therapy and management of all risk factors" },
    { label: "Common issues to exclude FIRST:", text: "Poor inhaler technique (up to 80%); poor adherence (up to 75%); incorrect diagnosis; comorbidities (rhinosinusitis, GERD, obesity); ongoing allergen/irritant exposure" },
    { label: "Evaluation:", text: "Confirm diagnosis → identify mechanism of persisting symptoms → assess adherence (multidisciplinary team if available)" },
  ];
  dtPts.forEach((pt, i) => {
    slide.addText(pt.label, { x: 0.3, y: 1.36 + i * 0.72, w: 4.4, h: 0.22, fontSize: 8.5, bold: true, color: "8B2020", fontFace: "Calibri" });
    slide.addText(pt.text, { x: 0.3, y: 1.56 + i * 0.72, w: 4.4, h: 0.45, fontSize: 8, color: DARK_TEXT, fontFace: "Calibri" });
  });

  // Difficult-to-treat clinical pathway figure
  try {
    slide.addText("Fig 7: Clinical Pathway – Difficult-to-Treat Asthma", { x: 0.25, y: 4.28, w: 4.5, h: 0.25, fontSize: 8.5, bold: true, color: MED_BLUE, fontFace: "Calibri" });
    slide.addImage({ data: imgBase64(IMG_DIR + "p15_X250.jpg"), x: 0.25, y: 4.5, w: 4.5, h: 1.1 });
  } catch(e) {}

  // RIGHT – FeNO + Self-Management
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 0.85, w: 4.7, h: 0.42, fill: { color: "1A4A8A" }, line: { color: "1A4A8A" }, rectRadius: 0.05 });
  slide.addText("FeNO-Guided Treatment (Rec. 4h) & Self-Management", {
    x: 5.15, y: 0.85, w: 4.6, h: 0.42, fontSize: 10, bold: true, color: WHITE, fontFace: "Calibri", valign: "middle"
  });

  // FeNO box
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 1.38, w: 4.7, h: 1.5, fill: { color: WHITE }, line: { color: ACCENT, pt: 1.2 }, rectRadius: 0.06 });
  slide.addText("FeNO as Adjunct to Guide Treatment", { x: 5.2, y: 1.43, w: 4.5, h: 0.3, fontSize: 10, bold: true, color: ACCENT, fontFace: "Calibri" });
  const fenoPoints = [
    "Recommendation 4h: FeNO CAN be used as adjunct (Weak recommendation, Low certainty)",
    "Meta-analysis of 23 RCTs (n=2,723 pediatric patients): FeNO-guided management reduced exacerbations (RR 0.73, 95% CI 0.63–0.84)",
    "Reduced exacerbation frequency (SMD −1.57, 95% CI −2.25 to −0.88)",
    "Note: GINA 2021 does not explicitly recommend FeNO-guided treatment — this is a de novo recommendation",
    "Sputum eosinophil count: Insufficient evidence in children (Cochrane 2017)",
  ];
  fenoPoints.forEach((fp, i) => {
    slide.addText(`• ${fp}`, { x: 5.2, y: 1.75 + i * 0.22, w: 4.5, h: 0.22, fontSize: 7.8, color: DARK_TEXT, fontFace: "Calibri" });
  });

  // Self-management box
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 3.0, w: 4.7, h: 1.6, fill: { color: WHITE }, line: { color: "1A6B3C", pt: 1.2 }, rectRadius: 0.06 });
  slide.addText("Guided Asthma Self-Management (GPS 4.2)", { x: 5.2, y: 3.05, w: 4.5, h: 0.3, fontSize: 10, bold: true, color: "1A6B3C", fontFace: "Calibri" });
  const selfMgmt = [
    "Train patients/families to independently adjust medications per their Written Asthma Action Plan (WAAP)",
    "Essential components: self-monitoring of symptoms and/or peak flow; clear & updated WAAP; regular physician review of control & inhaler skills",
    "Patients should know when to contact their physician for major treatment decisions",
    "Long-term pharmacologic agents require ongoing education on proper device use & adherence",
  ];
  selfMgmt.forEach((sm, i) => {
    slide.addShape(pres.ShapeType.ellipse, { x: 5.15, y: 3.42 + i * 0.28, w: 0.13, h: 0.13, fill: { color: "1A6B3C" }, line: { color: "1A6B3C" } });
    slide.addText(sm, { x: 5.35, y: 3.38 + i * 0.28, w: 4.4, h: 0.28, fontSize: 7.8, color: DARK_TEXT, fontFace: "Calibri", valign: "middle" });
  });

  // Take-home box
  slide.addShape(pres.ShapeType.rect, { x: 5.1, y: 4.68, w: 4.7, h: 0.52, fill: { color: DARK_BLUE }, line: { color: DARK_BLUE }, rectRadius: 0.06 });
  slide.addText("Key Principle: Asthma management is a continuous Assess → Adjust → Review cycle with shared decision-making between patients, caregivers, and healthcare providers.", {
    x: 5.2, y: 4.72, w: 4.5, h: 0.44, fontSize: 8.5, color: WHITE, fontFace: "Calibri", italic: true, valign: "middle"
  });

  slide.addText("Source: Philippine CPG on Asthma (GINA 2021 Adopted)", {
    x: 0.2, y: 5.56, w: 9.6, h: 0.16, fontSize: 7, italic: true, color: "999999", fontFace: "Calibri"
  });
}

// ── Write file ──────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/asthma_5_3/5_3_Long_Term_Asthma_Management.pptx" })
  .then(() => console.log("DONE: /home/daytona/workspace/asthma_5_3/5_3_Long_Term_Asthma_Management.pptx"))
  .catch(err => { console.error("ERROR:", err); process.exit(1); });
Running Command

cd /home/daytona/workspace/asthma_5_3 && node create_ppt.js 2>&1

Running Command

ls -lh /home/daytona/workspace/asthma_5_3/5_3_Long_Term_Asthma_Management.pptx

Your PPT is ready! Here's your download link:

5 3 Long Term Asthma Management

Presentation · PPTX

What's in the 5 Slides (all content from your PDF):

SlideTitleContent
1Overview & Long-term Goals3 management components, 3 GINA 2021 goals, Assess→Adjust→Review cycle with Figure 2 from PDF
2Treatment Steps by Age GroupSide-by-side columns for <6 yrs, 6–11 yrs, and 12–18 yrs with all 5 treatment steps
3Clinical Pathway FiguresFigure 3 (children <6 yrs) and Figure 4 (children 6–11 yrs) directly from your PDF
4Reviewing Response, Step-Down & ReferralStep-down principles, Figure 6 step-down strategy from PDF, indications for specialist referral
5Difficult-to-Treat Asthma, FeNO & Self-ManagementSevere/difficult asthma criteria, FeNO evidence (Rec. 4h), guided self-management components, Figure 7 from PDF
Design: Dark navy/blue color palette with accent teal, clean professional layout. All figures are extracted directly from your uploaded PDF and embedded into the slides.

Make me short and simple 5page canva pdf

Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.